460 Stock Overview
An investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Risk Analysis
No risks detected for 460 from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Sihuan Pharmaceutical Holdings Group Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.82 |
| 52 Week High | HK$1.02 |
| 52 Week Low | HK$0.49 |
| Beta | 0.58 |
| 1 Month Change | 30.16% |
| 3 Month Change | 32.26% |
| 1 Year Change | 36.67% |
| 3 Year Change | -31.67% |
| 5 Year Change | 13.89% |
| Change since IPO | -86.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 460 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 18.8% | 5.2% | 0.7% |
| 1Y | 36.7% | 9.5% | 10.8% |
Return vs Industry: 460 exceeded the Hong Kong Pharmaceuticals industry which returned 9.5% over the past year.
Return vs Market: 460 exceeded the Hong Kong Market which returned 10.8% over the past year.
Price Volatility
| 460 volatility | |
|---|---|
| 460 Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in HK Market | 15.1% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 460 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 460's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 2,667 | Weicheng Guo | www.sihuanpharm.com |
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China. The company operates through three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. It offers filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care, and others, as well as non- or minimally invasive medical aesthetics comprehensive solutions.
Sihuan Pharmaceutical Holdings Group Ltd. Fundamentals Summary
| 460 fundamental statistics | |
|---|---|
| Market cap | HK$7.50b |
| Earnings (TTM) | -HK$234.89m |
| Revenue (TTM) | HK$2.06b |
Is 460 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 460 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.90b |
| Cost of Revenue | CN¥659.40m |
| Gross Profit | CN¥1.24b |
| Other Expenses | CN¥1.46b |
| Earnings | -CN¥216.66m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 65.32% |
| Net Profit Margin | -11.40% |
| Debt/Equity Ratio | 17.8% |
How did 460 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 01:36 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sihuan Pharmaceutical Holdings Group Ltd. is covered by 24 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shaojing Tong | BofA Global Research |
| Harry He | China Galaxy International Securities (Hong Kong) |
| Sze Chuen Tam | Core Pacific -Yamaichi International (H.K.) Limited |